Newsletter Tool

Today’s Big News

Sep 4, 2024

ArsenalBio raises $325M for solid tumor CAR-T science with Regeneron and BMS in tow

Eli Lilly bets $1B in biobucks on Haya to scour dark genome for obesity targets

Athira's phase 2/3 Alzheimer's trial falls short, sinking stock

BioAge files for IPO, plans pair of midstage obesity trials

Acepodia and Pfizer Ignite click together to advance chemistry-based cell therapies

Aelis' cannabis use drug flunks phase 2b, driving Indivior to rethink $100M option

Moderna’s mpox vaccine prevents severe symptoms in monkeys compared to Bavarian Nordic’s Jynneos

Featured

ArsenalBio raises $325M for solid tumor CAR-T science with Regeneron and BMS in tow

By Gabrielle Masson

Arsenal Biosciences is moving on up. The cell therapy company has added on $325 million in ammunition with big-name backers like Regeneron joining the artillery.

Eli Lilly bets $1B in biobucks on Haya to scour dark genome for obesity targets

By Nick Paul Taylor

Eli Lilly’s hunt for obesity targets has led it to the dark genome. The Big Pharma has put together a deal worth up to $1 billion in biobucks to partner with Haya Therapeutics to find multiple regulatory-genome-derived RNA-based drug targets.

Athira's phase 2/3 Alzheimer's trial falls short, sinking stock

By Nick Paul Taylor

Athira Pharma’s tumultuous journey to phase 2/3 Alzheimer’s disease data has ended in failure. The trial found fosgonimeton was no better than placebo on the primary and key secondary endpoints, driving investors to cut the cord holding up the biotech’s stock price.

Fierce Biotech Editor-in-Chief Ayla Ellison Talks Shop with Michelle Benz on the Future of Biotech.

BioAge files for IPO, plans pair of midstage obesity trials

By Gabrielle Masson

After raising $170 million back in February, metabolic disease-focused BioAge Labs has filed to debut on the public markets.

Acepodia and Pfizer Ignite click together to advance chemistry-based cell therapies

By Darren Incorvaia

Call it a case of good chemistry: Acepodia, a biotech based on Nobel Prize-winning science, is entering into a new partnership with Pfizer’s Ignite program to support development of unique cell immunotherapies.

Aelis' cannabis use drug flunks phase 2b, driving Indivior to rethink $100M option

By Nick Paul Taylor

Aelis Farma’s hopes of securing a quick, positive decision on a $100 million option payment have gone up in smoke. The French biotech reported the failure of its phase 2b cannabis use disorder (CUD) study Wednesday, prompting its partner Indivior to say it doesn’t currently expect to exercise its option.

Moderna’s mpox vaccine prevents severe symptoms in monkeys compared to Bavarian Nordic’s Jynneos

By Darren Incorvaia

The rise of mpox has sparked a mad dash to develop new vaccines that are safer, more effective and easier to manufacture. Moderna, a biotech best known for its mRNA COVID-19 vaccine, has aimed its expertise in the messenger molecules at mpox.

Radiotherapy leader Novartis brings US isotope production in house, builds West Coast production plant

By Angus Liu

Novartis is further bolstering its radiotherapy infrastructure with a brand-new facility and the expansion of an existing site that will bring critical production of radioactive isotopes in house in the U.S.

EU high court hands Illumina consolation prize, ruling in favor of its appeal over Grail

By Conor Hale

Though Illumina has already parted ways with Grail, the DNA sequencing giant will not have to pay the European Union its $476 million fine.

Fierce podcasts

Don’t miss an episode

Driving flu vaccine uptake in the post pandemic era

In this week's episode of "The Top Line," we look at factors driving the continuing decline of flu vaccination rates in the U.S. and beyond.

Minimizing plastics use and risk in healthcare

The TROP2 race for supremacy

Resources

Whitepaper

Building a “Best Practice” Commercial Organization in Biopharma

We interviewed dozens of biopharma leaders on the critical success factors for building a Best Practice commercial organization. This report shares what we learned.

Epilepsy Clinical Trials

Finding an effective epilepsy treatment can be arduous. Download this brochure to delve into how IQVIA's expertise and innovative strategic approach can streamline the clinical trial process, helping to get new therapies to patients who need them sooner.